ArticleParasitology research2003
Fasciola hepatica: tegumental surface alterations following treatment in vivo and in vitro with nitroxynil (Trodax).
Article in Parasitology research, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Evaluating the In Vitro Anthelmintic Activity of Zinc Oxide Nanoparticles (ZnO-NPs) Against the Adult Stages of Fasciola hepatica.Veterinary medicine and science · 2025Article
- Ultrastructural Changes in the Tegument and Tissues of Fasciola hepatica Adults and Their Eggs Due to the Effect of an Ethyl Acetate Extract of Artemisia ludoviciana Nutt. spp Mexicana.Acta parasitologica · 2024Article
- Efficacy of flukicides onParasitology · 2022Article
- Article
- In vitro tegumental alterations on adult Fasciola gigantica caused by mefloquine.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2016Article
- The diterpenoid 7-keto-sempervirol, derived from Lycium chinense, displays anthelmintic activity against both Schistosoma mansoni and Fasciola hepatica.PLoS neglected tropical diseases · 2015Article
- Effects of Mirazid(®) and myrrh volatile oil on adult Fasciola gigantica under laboratory conditions.Asian Pacific journal of tropical biomedicine · 2012Article
- Cassia alata L: potential role as anthelmintic agent against Hymenolepis diminuta.Parasitology research · 2012Article
- Anthelmintic effect of a methanol extract of Bombax malabaricum leaves on Paramphistomum explanatum.Parasitology research · 2012Article
- Anthelmintic effect of a methanol extract of leaves of Dregea volubilis on Paramphistomum explanatum.Parasitology research · 2012Article
- Potentilla fulgens (Family Rosaceae), a medicinal plant of north-east India: a natural anthelmintic?Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2010Article
- Anthelmintic efficacy of ethanolic shoot extract of Alpinia nigra on tegumental enzymes of Fasciolopsis buski, a giant intestinal parasite.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2009Article
- Surface changes in adult Fasciola hepatica following treatment in vivo with the experimental fasciolicide, compound alpha.Parasitology research · 2009Article
- Morphological response of triclabendazole-susceptible and triclabendazole-resistant isolates of Fasciola hepatica to treatment in vitro with nitroxynil (Trodax).Parasitology research · 2009Article
- Ultrastructural changes induced in the tegument and gut of Fasciola hepatica following in vivo and in vitro drug treatment with nitroxynil (Trodax).Parasitology research · 2007Article
- Immature triclabendazole-resistant Fasciola hepatica: tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha.Parasitology research · 2007Article
- Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro.Parasitology research · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Male Sprague-Dawley rats were dosed orally with nitroxynil at a concentration of 40 mg/kg and adult Fasciola hepatica recovered after 24 h, 48 h and 72 h. Surface changes to the flukes were monitored by means of SEM. After the 24 h treatment, extensive swelling and blebbing of the tegument was observed on both surfaces, although the dorsal anterior region was more severely affected than either the posterior dorsal region or entire ventral surface. At high magnification, microvillus-like projections were evident, giving the surface a roughened appearance. After 48 h, the changes evident at 24 h had become more severe and some tegumental loss had occurred in the oral region of the fluke. Surface disruption was particularly evident along the lateral margins of the fluke in this region. In some specimens a single large swelling was present in the dorsal midbody region. The swelling was a more typical feature of flukes recovered. After 72 h, tegumental loss was more widespread, occurring over the oral cone and anterior midbody on the dorsal surface. Overall the dorsal surface was consistently more severely affected than the ventral surface, and the anterior region of the fluke was more disrupted than the posterior region. After 24 h in vitro incubation, the oral cone and midbody exhibited considerable spine loss and swelling. Overall, the dorsal surface was more disrupted than the ventral surface and the anterior region of the fluke was more disrupted than the posterior region. Regional differences in the response of the fluke to nitroxynil will be compared to previously published data with other fasciolicides. The results indicate that the tegument is an important target for nitroxynil action. Disruption of this, the fluke's main line of defence, would allow the drug access to other internal tissues, leading to more widespread damage.
Indexed as
Identifiers
12937960What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.